Immatics (IMTX) Competitors $5.35 +0.01 (+0.19%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends IMTX vs. ACAD, VCEL, XENE, MLTX, MOR, DNLI, MRUS, ZLAB, SWTX, and BHCShould you be buying Immatics stock or one of its competitors? The main competitors of Immatics include ACADIA Pharmaceuticals (ACAD), Vericel (VCEL), Xenon Pharmaceuticals (XENE), MoonLake Immunotherapeutics (MLTX), MorphoSys (MOR), Denali Therapeutics (DNLI), Merus (MRUS), Zai Lab (ZLAB), SpringWorks Therapeutics (SWTX), and Bausch Health Companies (BHC). These companies are all part of the "pharmaceutical products" industry. Immatics vs. ACADIA Pharmaceuticals Vericel Xenon Pharmaceuticals MoonLake Immunotherapeutics MorphoSys Denali Therapeutics Merus Zai Lab SpringWorks Therapeutics Bausch Health Companies ACADIA Pharmaceuticals (NASDAQ:ACAD) and Immatics (NASDAQ:IMTX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, community ranking, institutional ownership, earnings, analyst recommendations, valuation and dividends. Which has stronger earnings and valuation, ACAD or IMTX? ACADIA Pharmaceuticals has higher revenue and earnings than Immatics. Immatics is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioACADIA Pharmaceuticals$726.44M4.02-$61.29M$0.7822.53Immatics$58.44M10.93-$104.98M-$0.66-8.11 Do institutionals and insiders believe in ACAD or IMTX? 96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. Comparatively, 64.4% of Immatics shares are held by institutional investors. 28.3% of ACADIA Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Is ACAD or IMTX more profitable? ACADIA Pharmaceuticals has a net margin of 13.83% compared to Immatics' net margin of -47.94%. ACADIA Pharmaceuticals' return on equity of 25.83% beat Immatics' return on equity.Company Net Margins Return on Equity Return on Assets ACADIA Pharmaceuticals13.83% 25.83% 14.71% Immatics -47.94%-15.90%-9.38% Do analysts prefer ACAD or IMTX? ACADIA Pharmaceuticals currently has a consensus price target of $25.25, indicating a potential upside of 43.71%. Immatics has a consensus price target of $16.67, indicating a potential upside of 211.53%. Given Immatics' stronger consensus rating and higher probable upside, analysts plainly believe Immatics is more favorable than ACADIA Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ACADIA Pharmaceuticals 0 Sell rating(s) 7 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.59Immatics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Does the MarketBeat Community prefer ACAD or IMTX? ACADIA Pharmaceuticals received 863 more outperform votes than Immatics when rated by MarketBeat users. However, 75.00% of users gave Immatics an outperform vote while only 73.14% of users gave ACADIA Pharmaceuticals an outperform vote. CompanyUnderperformOutperformACADIA PharmaceuticalsOutperform Votes89373.14% Underperform Votes32826.86% ImmaticsOutperform Votes3075.00% Underperform Votes1025.00% Which has more risk and volatility, ACAD or IMTX? ACADIA Pharmaceuticals has a beta of 0.37, indicating that its share price is 63% less volatile than the S&P 500. Comparatively, Immatics has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500. Does the media prefer ACAD or IMTX? In the previous week, ACADIA Pharmaceuticals had 7 more articles in the media than Immatics. MarketBeat recorded 12 mentions for ACADIA Pharmaceuticals and 5 mentions for Immatics. ACADIA Pharmaceuticals' average media sentiment score of 0.56 beat Immatics' score of 0.21 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ACADIA Pharmaceuticals 4 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immatics 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral SummaryACADIA Pharmaceuticals beats Immatics on 13 of the 19 factors compared between the two stocks. Get Immatics News Delivered to You Automatically Sign up to receive the latest news and ratings for IMTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMTX vs. The Competition Export to ExcelMetricImmaticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$638.58M$2.96B$5.21B$9.14BDividend YieldN/A1.91%5.13%4.02%P/E Ratio-8.1145.5689.4217.36Price / Sales10.93275.871,240.0477.11Price / CashN/A192.9043.7535.97Price / Book1.863.965.314.79Net Income-$104.98M-$41.02M$122.54M$225.00M7 Day Performance-10.39%1.13%1.42%2.37%1 Month Performance-21.90%-1.72%2.50%4.40%1 Year Performance-53.28%-2.23%25.29%20.10% Immatics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMTXImmatics1.6259 of 5 stars$5.35+0.2%$16.67+211.5%-53.3%$638.58M$58.44M-8.11260Short Interest ↑Gap UpACADACADIA Pharmaceuticals4.0907 of 5 stars$17.90+3.7%$25.25+41.1%-35.6%$2.98B$929.24M22.95510Short Interest ↑VCELVericel1.926 of 5 stars$59.62+0.2%$61.14+2.6%+48.9%$2.94B$226.84M993.83300XENEXenon Pharmaceuticals2.7564 of 5 stars$38.25-0.4%$56.00+46.4%-12.0%$2.92B$9.43M-13.56210Positive NewsMLTXMoonLake Immunotherapeutics1.9821 of 5 stars$45.26-2.3%$81.43+79.9%-18.2%$2.89BN/A-35.092Analyst UpgradeGap UpMORMorphoSys0.2266 of 5 stars$18.96flat$14.33-24.4%N/A$2.86B$238.28M-5.45730DNLIDenali Therapeutics4.3872 of 5 stars$19.59+2.6%$38.91+98.6%+28.3%$2.82B$330.53M-7.10430Short Interest ↑MRUSMerus3.0447 of 5 stars$40.45-7.8%$85.64+111.7%+12.7%$2.77B$35.93M-10.2437High Trading VolumeZLABZai Lab2.7048 of 5 stars$25.21-0.4%$55.00+118.2%+11.1%$2.76B$355.75M-9.102,175SWTXSpringWorks Therapeutics1.5283 of 5 stars$37.01-13.9%$70.00+89.1%-13.1%$2.75B$135.49M-9.54230BHCBausch Health Companies3.3414 of 5 stars$7.40-6.1%$7.75+4.7%-8.8%$2.68B$9.47B-15.4220,270Short Interest ↓Positive NewsHigh Trading Volume Related Companies and Tools Related Companies ACADIA Pharmaceuticals Competitors Vericel Competitors Xenon Pharmaceuticals Competitors MoonLake Immunotherapeutics Competitors MorphoSys Competitors Denali Therapeutics Competitors Merus Competitors Zai Lab Competitors SpringWorks Therapeutics Competitors Bausch Health Companies Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IMTX) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immatics Please log in to your account or sign up in order to add this asset to your watchlist. Share Immatics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
